**Name of journal: *World Journal of Hepatology***

**ESPS Manuscript NO: 12684**

**Columns: REVIEW**

**Incidence, risk factors and outcome of *de novo* tumors in liver transplant recipients focusing on alcoholic cirrhosis**

Carlos JR *et al.* Posttransplant tumors in alcoholic recipients

Jiménez-Romero Carlos, Justo-Alonso Iago, Cambra-Molero Félix, Manrique-Municio Alejandro, Calvo-Pulido Jorge, García-Sesma Álvaro, Abradelo-Usera Manuel, Caso-Maestro Oscar, Moreno-González Enrique

**Jiménez-Romero Carlos, Justo-Alonso Iago, Cambra-Molero Félix, Manrique-Municio Alejandro, Calvo-Pulido Jorge, García-SesmaÁlvaro, Abradelo-Usera Manuel, Caso-Maestro Oscar, Moreno-González Enrique,** Service of General and Digestive Surgery, Abdominal Organ Transplantation, “Doce de Octubre”, University Hospital, Universidad Complutense de Madrid, 28041 Madrid, Spain

**Author contributions:** All authors equally contributed to this paper.

**Conflict-of-interest:** None to declare.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to: Carlos Jiménez-Romero, MD, PhD, FACS,** Service of General and Digestive Surgery, Abdominal Organ Transplantation, “Doce de Octubre”, University Hospital, Universidad Complutense de Madrid, Ctra de Andalucía km 5,4., 28041 Madrid, Spain. luiscarlos.jimenez@salud.madrid.org

**Telephone:** +34-91-3908077

**Fax:** +34-91-3908077

**Received:** July 21, 2014

**Peer-review started:** July 28, 2014

**First decision:** August 14, 2014

**Revised:** September 15, 2014

**Accepted:** February 4, 2015

**Article in press:**

**Published online:**

**Abstract**

Orthotopic liver transplantation (OLT) is an established life-saving procedure for alcoholic cirrhotic (AC) patients, but the incidence of *de novo* tumors ranges between 2.6% and 15.7% and is significantly increased in comparison with patients who undergo OLT for other etiologies. Tobacco, a known carcinogen, has been reported to be between 52% and 83.3% in AC patients before OLT. Other risk factors that contribute to the development of malignancies are dose-dependent immunosuppression, advanced age, viral infections, sun exposure, and premalignant lesions (inflammatory bowel disease, Barrett´s esophagus). A significantly more frequent incidence of upper aerodigestive (UAD) tract, lung, skin, and kidney-bladder tumors has been found in OLT recipients for AC in comparison with other etiologies. Liver transplant recipients who develop *de novo* non-skin tumors have a decreased long-term survival rate compared with controls. This significantly lower survival rate is more evident in AC recipients who develop UAD tract or lung tumors after OLT mainly because the diagnosis is usually performed at an advanced stage. All transplant candidates, especially AC patients, should be encouraged to cease smoking and alcohol consumption in the pre- and post-OLT periods, use skin protection, avoid sun exposure and over-immunosuppression, and have a yearly otopharyngolaryngeal exploration and chest CT scan in order to prevent or reduce the incidence of *de novo* malignancies. Although still under investigation, substitution of calcineurin inhibitors for sirolimus or everolimus may reduce the incidence of *de novo* tumors after OLT.

**Key words:** *De novo* malignancies; *De novo* tumors tobacco consumption; Alcoholic cirrhosis; *De novo* cancer; Liver transplant

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Incidence of *de novo* tumors is significantly increased in patients who undergo liver transplantation for alcoholic cirrhosis. The association of alcohol and tobacco consumption and immunosuppression contribute to the development of *de novo* malignacies, mainly located in upper aerodigestive tract, lung and skin.

Carlos JR, Iago JA, Félix CM, Alejandro MM, Jorge CP, Álvaro GS, Manuel AU, Oscar CM, Enrique MG. Incidence, risk factors and outcome of *de novo* tumors in liver transplant recipients focusing on alcoholic cirrhosis. *World J Hepatol* 2015; In press

**INTRODUCTION**

The occurrence of *de novo* tumors is considered the second cause of late mortality after orthotopic liver transplantation (OLT)[1-3]. Initially, similar frequency of *de novo* tumors (carcinomas of the lung, prostate, breast, colon, and uterine cervix) was published among transplant recipients in comparison with the non-transplant population[4]**.** Subsequently, a higher incidence of posttransplant lymphoproliferative disease (PTLD) and skin cancer was established in OLT patients *vs* non-immunosuppressed population[2,5-7]**.** Moreover, the incidence of other tumors is controversial so that, depending on the series of OLT, an increased incidence of upper aerodigestive (UAD) tract[1,5,6,8-16], colon[5,6,17], and kidney tumors[5] can be found. It has been reiterated that the most important contributing factors for increased incidence of *de novo* tumors are the long period of follow-up of the recipients and the presence of risk factors, such as abuse of alcohol and tobacco, sun exposure, overimmunosuppression, advanced age, inflammatory bowel disease, HBV and HCV infections, Epstein-Barr virus, herpes virus 8, and human papilloma virus[5,8,11,14,18-21]. Alcoholic cirrhosis (AC) constitutes the leading cause of end-stage liver disease in Western countries, and many of these patients may potentially benefit from OLT if they fulfill the usual criteria for this technique[22]. However, the OLT patients for AC show an increased incidence of *de novo* malignancies after transplant[9,11-16,23-32].

 The objective of this review is to analyze the incidence, risk factors, location and characteristics of *de novo* tumors in AC patients who underwent OLT, and also to evaluate the prognosis and survival after diagnosis of malignancies.

METHODS

We performed MEDLINE search considering the most important series related with *de novo* tumors after OLT that were reported in English literature. We analysed the incidence of *de novo* malignancies in OLT recipients in comparison with the non-transplant population as control group, and also we will mainly focuss on the different series which studied the incidence, risk factors and predisposing conditions for developing *de novo* tumors, locations, survival after diagnosis, surveillance, and immunosuppression changes as prevention or therapeutics measures for control these tumors. In addition, we analysed the incidence of *de novo* tumors in comparative studies between alcoholic and non-alcoholic recipients of OLT.

INCIDENCE

Overall incidence of *de novo* tumors after OLT ranges between 2.6 and 33.6%[1,2,5-8,11,12,16,17,25,26,32-44] (Table 1). The disparity of *de novo* tumors incidence among these series is attributed to exclusion of some type of tumors, such PTLD in the study of Saigal *et al*[26] (incidence of 2.6%). The increased incidence of *de novo* tumors after OLT is mainly due to the intensive surveillance, and the life-long immunosuppressive therapy the transplant recipients receive[1,5]. In our series of 528 adult transplant recipients with a mean follow-up of 6.7 years, the cumulative risks for development of non-cutaneous malignancies at 5, 10, and 15 years post-OLT, were 9%, 18%, and 25%, respectively[45]. A recent series reports a 15-year cumulative incidence of *de novo* tumors of 34.7% as compared to 8.9% for the non-transplant population, and emphasizes the continuously increasing incidence of tumors over time following OLT[44]. The mean interval between OLT and tumor diagnosis was reported to be between 19.2 and 82.7 months, and the mean age of recipients at the time of diagnosis was between 53 and 59.5 years[14,32,37,38,44]. A significantly higher incidence has been observed in patients who underwent OLT for AC in comparison with other non-AC diseases[9,11-13,15,23,24,26,28,29] (Table 2). In our series of 701 adult recipients of OLT, the incidence of *de novo* tumors in AC patients was significantly higher (25% in AC patients *vs* 9.4% in non-AC recipients; *P* < 0.001)[28].

**RISK FACTORS AND PREDISPOSING CONDITIONS FOR *DE NOVO* TUMORS AFTER OLT FOR AC PATIENTS**

***Recipient age***

Liver transplant series showed recipients older than 40 years[5], and older than 51 years old at the time of OLT[25] as having independent risk for *de novo* malignancies. In two recent studies it was also observed that older age and smoking were independently associated with a higher risk of malignancy[38,46], especially lung, head and neck, kidney and urinary tract[46].

***Tobacco and alcohol consumption***

Prevalence of tobacco use among the non-transplant population is between 20% and 30%, and as high as 40% in OLT recipients[47].

Smoking fewer cigarettes over a long period seems more damaging than smoking more cigarettes over a shorter period[47]. Tobacco discontinuation is usually required for heart and lung transplantation candidates, but in OLT candidates the requirement of smoking discontinuation is less clear and remains controversial. The association of alcohol and tobacco consumption has been published to be as high as 90% in alcoholic patients[48,49]. It has been documented that 52% of AC patients were active smokers before OLT and 44% after OLT[50]. In our series of OLT for AC, 83.3% of patients were smokers *vs* 43% of non-AC patients[28]. Smokers show an increased risk of cardiovascular disease, stroke and cancer[51]. Moreover, tobacco consumption has also been associated with squamous cell carcinoma (SCC) of the skin in the non-transplant population[52] and OLT recipients[20,27]. In addition, malignancies seem to develop much earlier after OLT in tobacco users[50]. In a comparative study among active smokers, ex-smokers, and non-smokers who underwent OLT, a significantly increased cardiovascular-specific mortality and sepsis mortality but not malignancy-related mortality was demonstrated in the active smokers group[53]. On the other hand, other authors showed a significantly higher 10-year cumulative rate of *de novo* tumors in active smokers (12.7%) *vs* non-smokers (2.1%), but without an effect of smoking on skin cancer or cardiovascular disease[50]. Liver transplant recipients who ceased smoking had a lower incidence of such tumors in comparison with patients who continued to smoke[46].

A synergistic effect has been demonstrated when patients are exposed to combined alcohol and tobacco consumption, resulting in a more than 7-fold increased risk of tumors[54,55]. In the general population, tobacco and alcohol abuse are well-known risk factors for oral, pharyngeal, laryngeal, esophageal, upper airway, bladder and cervix tumors[54,56-60]. In a more recent review of the non-transplant population, a causal association was established between alcohol intake and cancers of the oral cavity, pharynx, larynx, esophagus, liver, colon, rectum, and in women, breast[61,62]; an association is suspected for cancers of the pancreas and lung[61]. However, the carcinogenic effects of alcohol have not been fully defined and probably differ by target organ. Alcoholic drinks might act as a solvent for carcinogens (*e.g.,* tobacco-derived), facilitating penetration through the mucosa of the upper aerodigestive organs[63]. Heavy alcohol intake seems to affect folate metabolism which changes DNA methylation and the control of expression of genes with a potential role in carcinogenesis (colon, rectum and breast)[64]. For breast cancer, alcohol carcinogenicity is thought to be due to increased estrogen concentration[65]. Production of reactive oxygen species and nitrogen species is a possible mechanism of alcohol-related liver carcinogenesis[66].

Alcoholic cirrhotic patients have a longer history of tobacco use than the general population[67] and also a higher tobacco consumption than patients undergoing OLT for other etiologies[9,35]. Multivariate analysis of a series from the Mayo Clinic showed an increased probability of developing any solid organ *de novo* malignancy with increased age, a history of smoking, and AC or primary sclerosing cholangitis as indications for OLT[14]. In our experience, there is a significantly higher incidence of *de novo* tumors (overall and partial incidence of skin, upper aerodigestive, and lung tumors) in AC patients compared with non-AC patients, a feature that is also related with a significant consumption of alcohol and tobacco in the AC group[27,28,35].

After 10 years of smoking, OLT recipients presented a significantly higher risk of non-skin tumors[51]. It has also suggested that alcohol abuse can produce genetic alterations that potentiate those induced by tobacco smoke[60], and tobacco can also alter the cellular immune system by decreasing the number of natural killer cells[68,69].

The association of immunosuppressive drugs and smoking may have adverse additive effects, mainly in liver transplant patients for AC with a long history of alcohol and tobacco abuse, where there has been a demonstrated higher incidence of UAD and lung *de novo* tumors[1,9-11,14,18,23-25,27,28,45,46,70,71] and even bladder[46] or skin tumors[23,27] .

***Infections***

Kaposi´s sarcoma (KS) is a tumor exclusively seen in the immunocompromised patients and is clearly related with type 8 human herpes virus[72]. Human papillomavirus increases the risk for anal, genitourinary, oropharyngeal, and skin tumors, and even for cervical cancer in kidney transplant recipients[73]. PTLDs are associated with Epstein-Barr virus-infected B-lymphocytes and have been reported to have an incidence between 1.7 and 4% after OLT[21,74]. The incidence of PTLD is lower in OLT recipients in comparison with other solid organ transplants[74].

***Immunosuppression***

The influence of immunosuppression on the development of *de novo* tumors has been directly related to the intensity as well as the cumulative dose of immunosuppressive drugs[75].

Cyclosporine (CyA) and tacrolimus promote the spread of tumors in immunodeficient mice, probably by increasing the production of growth factors that enhance angiogenesis, tumor growth and metastasis[76]. The pathogenic process triggered by immunosuppressors consists of direct damage to the host DNA and impairment of the recipient´s immunosurveillance, which reduce their antitumor and antiviral immunity[77,78]. A retrospective study suggested a dose-dependent immunosuppressive drug relationship with *de novo* tumor development[11]. By contrast, other authors did not find that immunosuppression is an independent risk factor for *de novo* malignancy[26]. Several studies found a higher *de novo* tumor risk for CyA-based[33,38,45] or tacrolimus-based[36,44], whereas others did not observe significant differences between CyA- and tacrolimus-based immunosuppressive therapy[18,38,79]. It was pointed out that CyA therapy increased malignancy risk when C2 monitoring (blood concentration at 2 hours post-dose) was performed and the patient consequently received a significantly higher CyA dose[40]. Azathioprine has also been described as an independent risk factor for higher incidence of *de novo* malignancy, mainly due to inhibition of DNA repair, and its metabolite 6-thioguanine has been shown to accumulate in skin cells *in vitro*[80]. A recent report revealed that standardized incidence ratio for *de novo* tumors were similar for patients who received tacrolimus- or CyA-based immunosuppressive protocols as long-term immunosuppression (mean = 7.4 years) with or without mycophenolate mofetil, azathioprine, or prednisolone as a co-medication[16]. As summary, there are no randomized control studies designed to evaluate the influence of different immunosuppression schedules over the development of post-OLT *de novo* malignancies.

***Premalignant conditions***

Barrett´s esophagus is a premalignant condition with increased risk for development of esophageal tumor; a rapid progression to high-grade of dysplasia has been reported after OLT[81], as well as the development of esophageal carcinoma[82].

There has been suggested an increased incidence in colorectal *de novo* tumors in patients with ulcerative colitis or sclerosing cholangitis who underwent OLT[19,83].

Screening for premalignant conditions should be performed in a pre-OLT evaluation, and patients with evidence of a premalignant state should be followed carefully after OLT for detection of malignancy[84]. Because of the increased incidence of *de novo* tumors in AC (frequently smokers), these candidates should be subjected to thorough evaluation to rule out tumor or premalignant condition before OLT[15]. Thus, these patients should be screened for oropharyngeal/laryngeal, esophageal, lung, bladder, and skin tumors as the most frequent tumors associated with alcohol and tobacco consumption.

**LOCATION OF *DE NOVO* TUMORS IN OLT RECIPIENTS FOR AC**

We analyzed the subset of *de novo* tumors that are usually developed in patients who undergo OLT because of AC. Thus, a significantly more frequent incidence has been published of UAD tract, lung, skin, and bladder tumors in liver transplant patients for AC. PTLD is the second most frequent *de novo* tumor after OLT, but it is not associated with AC. Other types of solid tumors, such as gastric, pancreatic, colorectal, prostate, breast, and uterine cervix tumors show a similar incidence after OLT for AC and non-AC recipients. Risk factors for most frequent *de novo* tumors after OLT for AC are shown in Table 3.

***Upper aerodigestive tract tumors***

In this group a subset of tumors located in the floor of the mouth, tonsil, tongue, pharynx, larynx and esophagus is included, which are significantly more frequent in male and smoker recipients who underwent OLT for AC[1,9,10,14-16,23,24,30,33,36]. In some series, the most common solid tumors were tumors of the UAD tract[32,38]. The incidence of UAD tumors in OLT recipients was published to be between 0.3 and 3.5% in several series[1,6,10,11,18,33]. The risk of the development of oropharyngeal/laryngeal malignancies was highest in AC patients, with 5- and 10-year risks of 3.2% and 4.6%, respectively, *vs* 0.16% and 0.32%, respectively, for non-AC patients[14]. In patients who underwent OLT for AC, the rate of UAD tumors was 25.5 times higher than in patients with other etiologies[23]. The mean time from OLT to diagnosis of UAD tract tumors was reported to be between 24 and 62 months after OLT[1,6,10,11,18,33]. In one series, UAD tract malignancies occurred exclusively in patients transplanted for AC[9]. In one of our studies, the incidence was also significantly higher in the AC group (8.1%) *vs* the non-AC group (0.8%), and among the patients who suffered UAD tract tumors 70% were heavy smokers and 75% had a history of heavy drinking[10]. In patients who underwent OLT for AC, immunosuppressors may enhance the effects of alcohol and tobacco, which are well-known risk factors for the development of UAD tract tumors[85,86].

The pathogenic mechanism of esophageal carcinoma remains unclear. However, experimental studies in animals suggest that oxidative damage from smoking and alcohol intake, or gastroesophageal reflux, which produces inflammation, esophagitis, and increased cell turnover, might iniciate the carcinogenic process[87]. Esophageal *de novo* tumors have been diagnosed between 8 and 96 months after transplant in patients who smoke and who underwent OLT for AC[8,88,89]. In a German series[89] of 10 *de novo* esophageal tumors, diagnosed at a mean time of 51 months after OLT, all patients were males, 9 underwent OLT for AC and 1 for hepatocarcinoma, 3 were smokers, 9 were immunosuppressed with CyA, whereas 7 patients revealed squamous cell carcinoma (SCC) and 3 adenocarcinoma. Five of these patients were treated with chemo-radiotherapy and the other 5, who had a better general condition, underwent Ivor Lewis esophagectomy. In our published experience of 5 patients with *de novo* esophageal SCC, all were male and smokers, and underwent OLT for AC; diagnosis of SCC was performed at a mean time of 36 months after OLT, and four patients were treated by transhiatal esophagectomy, showing a 3-year patient survival of 40%[90]. In spite of the elevated risk of OLT patients who suffer esophageal tumors, the mortality after surgical resection was reported as zero in both series[89,90]. To date, there is no experience of neoadjuvant chemo-radiotherapy associated with esophagectomy for the treatment of esophageal tumors after OLT, but the results for surgery are comparable with non-transplant patients who present with an esophageal cancer[89,90] .

***Lung tumors***

The incidence of *de novo* lung tumors after OLT is increased, and ranges between 0.1% and 2.4%[1,11,18,25,28,36,38,91,92]. Our incidence of these malignancies is 40-fold higher than that of the non-transplant population in Spain[28]. The main risk factors for post-OLT lung tumors are the longer time elapsed since transplant[3], AC as indication for OLT[1,11,24,28,32,46], and a long period of tobacco consumption[1,14,28,36,38,91,92]. The risk of developing a lung cancer was highest in AC patients, with 5- and 10-year risks of 2.0% and 4.8%, respectively, compared to non-AC patients with 0.15% and 1.3%, respectively[14] .

 In several small series[91-93] all patients with *de novo* lung malignancies had indicated the antecedent of heavy smoking, and this addiction was also present in 62.5% of patients in Pittsburgh series[1] and in 83.3% in our series[28]. According to our experience, the continuation of smoking after OLT represents an additional risk factor for lung cancer[28]. The mean time from OLT to tumor diagnosis was reported to be between 42 and 83 months[1,6,18,28,92]. The mean age of our patients at the time of lung tumor diagnosis was significantly lower than a Spanish non-transplant population [94].

Patients with lung tumors after OLT show similar symptoms to non-transplant patients[1,28,93]. These lung tumors are usually diagnosed at advanced stages[1,18,28,36,95] in almost two-thirds of cases[28,93]. To obtain early diagnosis of a potentially curable stage of lung cancer, the goal is to perform screening with a CT scan every year of recipients at increased risk, especially in the subset of older recipients, over-immunosuppressed patients and smokers of more than 20-30 pack-year who have undergone OLT for AC[28,46,93,95-98].

According to OLT series[1,18,28,33,91], lung tumor resection can only be performed at early stages (I or II) and when the patients are in good general condition. In several reported series[1,28,33,36,91-93], there is little information about surgical resection of *de novo* lung tumors after OLT, but among 58 collected cases of these series there were only 13 resected cases (20.6%). In unresectable patients, palliative chemo and/or radiotherapy is an alternative option[1,8,18,28,93].

***Skin tumors***

Nonmelanoma skin cancer is the most common tumor in the post-OLT population, with an up to 70 times higher incidence in comparison with non-transplant patients[5,1025,99-101]. Tobacco constitutes a risk factor for skin malignancies in non-transplant patients[53]. The overall incidence in most OLT series ranges from 1% to 6.9%[1,5,11,18,27,33]. Skin tumors represent between 16% and 55% of all tumors and can develop at any time after OLT[20,27,36,40]. The cumulative incidence of nonmelanoma skin malignancies 5, 10, and 15 years after OLT has been reported to be 5.1%, 10.2% and 19.7%, respectively [40].

A long history of sun exposure, personal or family history of actinic keratosis or skin cancer, human papillomavirus, male sex, patient age, red hair, brown eyes, primary sclerosing cholangitis, hepatocarcinoma[14,20,25,36,102], AC and smoking[1,24,27] are described as risk factors for the development of skin tumors. The most frequent sites for *de novo* skin tumors were the face, lips, head, neck, and ears[1,20,27]. As in the non-transplant population, in some series the most common histologic tumor type was basal cell carcinoma[27,103], in contrast to other experiences where SCC was the most frequent[1,20]. Immunosuppressors increase the risk of skin cancer, but whether CyA shows a higher risk in comparison with tacrolimus is unclear. Thus, in one series CyA-treated patients have been associated with a higher incidence and earlier development of skin tumors[20], but another series failed to find significant differences between CyA and tacrolimus[18]. Nonmelanoma skin cancer does not affect mortality[40].

The incidence of KS ranges from 0.14 to 2.8% after OLT[99]. Viral infections, such as HBV, CMV, and Epstein-Barr virus infections have been reported as risk factors for KS, but the main risk factor is human herpes virus 8[104,105]. Kaposi´s sarcoma has been related with the degree of immunosuppression, and the lesions disappeared after immunosuppressive drugs were discontinued[106]. Almost all reported cases of KS are located on the skin, but some visceral cases with bad prognosis have also been described[72]. Full-skin examination may detect every kind of skin malignancy, such as melanoma, nonmelanoma cancer, KS or cutaneous lymphoma[107].

***Genitourinary and gynecological tumors***

Regular and current cigarette smokers in the non-transplant population have a higher risk of bladder cancer than those who never smoked, and there is a statistically significant dose-response relationship in bladder cancer risk between smoking duration, intensity and pack-year consumption[48]. People who discontinued smoking for 20 years or more remain at a higher risk of bladder cancer than people who never smoked, suggesting an early-stage irreversible effect of cigarette smoke[108,109].

 Considering the frequent consumption of tobacco among AC patients, the incidence of bladder tumors after OLT must be increased in this group of patients. However, there is little information about the increased incidence of bladder tumors in smokers, except for a recent report where smoking and older age were associated with a higher risk of urinary tract and kidney tumors[46]. An earlier series of OLT reported a 30-fold increase in *de novo* kidney tumors[5].

It appears that the rate of non-prostate genitourinary tumors is increased in OLT patients, but the rate of prostate cancer may be comparable to that in the non-transplant population[31]. The incidence of non-prostate genitourinary cancer in OLT patients ranges between 0% and 0.4%[11,91]. Other authors did not find an increased incidence of breast, cervix or bladder tumors in OLT compared with the non-transplant population[12,32].

**SURVIVAL AFTER DIAGNOSIS OF DE NOVO TUMORS**

The increased mortality associated with *de novo* tumors is thought to be the consequence of aggressive immunosuppression that may give rise to increased proliferation and spread of the tumor, which in turn results in more advanced stages of disease at presentation, precluding surgical or chemo-radiotherapy options[14].

Patients with *de novo* non-skin cancer after OLT have diminished long-term survival in comparison with controls[23,37,40,110]. Aerodigestive tract malignancies after OLT are greater causes of morbidity and mortality than recurrent alcohol liver disease[10,13]. *De novo* cancer-related death accounted for 21% of all deaths in patients surviving more than six months after OLT, and post-OLT survival was significantly lower in patients who developed *de novo* malignancy in comparison with patients without cancer (70% *vs* 82% at five years)[38]. In a series of 21 UAD and lung tumors diagnosed in 20 OLT recipients, 1-, 2-, and 3-year survival rates were 47.6%, 37.0% and 19.7%, respectively[10]. Moreover, in our series of 15 *de novo* lung tumors all patients died, and mean survival after tumor diagnosis was only 5.4 months[28]. A recent study considering smoking-related malignancies (lung, head and neck, esophageal, kidney and urinary tract tumors) reports a significantly higher mortality in OLT recipients *vs* the non-transplant patients[46].

Once the tumor was diagnosed, and according to the specific site of the *de novo* tumors, the probability of death at 1 and 5 years was 33% and 48%, respectively, for gastrointestinal tumors; 59% and 84%, respectively, for lung tumors; 22% and 44%, respectively, for oropharyngeal/laryngeal tumors; and 21% and 29%, respectively, for genitourinary tumors[14].

**SURVEILLANCE OF TRANSPLANT PATIENTS FOR AC**

While smoking and alcohol use, age and existence of premalignant conditions generate suspicion for *de novo* tumor development, prevention and screening after OLT is of paramount importance[14,30,31]. Thus, pre-OLT screening is advised for candidates with Barrett´s esophagus[111]. Moreover, all transplant patients who undergo OLT for AC and have a long history of smoking must be carefully reviewed for malignancy in the post-OLT setting, particularly in the oropharyngeal, laryngeal, lung [14,28,30,32,46], esophageal[46], skin[27], and kidney-bladder locations[46].

 Periodic patient controls in outpatient clinic and patient education on the importance of preventive screenings are of vital importance. Thus, all OLT candidates should be encouraged to cease smoking and alcohol intake (for a minimum period of 6 months to be included on the transplant waiting list). After OLT for AC, the recipients should continue with complete alcohol abstinence, avoidance of tobacco consumption, using sun protection with sunscreen and limiting sun exposure, undergo regular skin assessments, and routinely adhere to cancer screening tests[112,113]. Annual oto-pharyngo-laryngeal evaluation is advised in order to obtain early tumor detection[113]. Smokers of more than 20 pack-years who are actively smoking or have ceased tobacco abuse less than 10 years before OLT should be subjected every year to otolaryngeal evaluation and low-radiation CT scan[114]. Other authors only recommend annual chest X-rays for lung tumor screening[113].

**IMMUNOSUPPRESSION CHANGES AS PREVENTION OR TREATMENT OF *DE NOVO* TUMORS**

In long-term follow-up the maintenance drugs (CyA and tacrolimus) are associated with side effects such as cardiovascular complications, nephrotoxicity, neurotoxicity, diabetes, hepatocarcinoma recurrence, and the development of *de novo* malignancies[1,115,116]. The main objective is to get effective immunosuppression, while no promoting cancer development[117].

 Higher degrees of immunosuppression increase the risk of tumor after transplant in a dose-dependent manner[118]. Recently, two immunosuppressive drugs, mycophenolate mofetil[119,120], and the inhibitors of mammalian target of rapamycin (mTORi: sirolimus and everolimus)[121-123] have shown protective effects against the development of cancer. However, there are no published controlled trials evaluating the effect of m-TORi in preventing *de novo* tumors or recurrence of hepatocarcinoma after OLT[117,124].

Although much additional research is needed, several studies indicate that m-TORi may be effective in the prevention of malignancies, since a significantly reduced incidence of *de novo* malignancies was demonstrated when rapamycin was used alone or in combination with a reduced dose of CyA or tacrolimus[125], or combined with steroids only[126]. In addition, there is clinical evidence of the ability of sirolimus to suppress cancer progression in humans, as has been demonstrated in several kidney transplant series, 2 cases of complete remission of cutaneous Kaposi´s sarcoma[127], and 12 cases of remission of *de novo* lymphoma[128]. A multicenter prospective clinical trial assessing the effectiveness of m-TORi in avoiding the development of malignancies after OLT is currently under way in patients transplanted for hepatocarcinoma[129].

Nevertheless, the remarkable reduction of all *de novo* posttransplant malignancies and the excellent regression/control of the most common tumors in the early stages with m-TORi immunosuppression is a strong reason to expand the role of m-TORi in maintenance immunosuppressive therapy[130]. Immunosuppression protocols using sirolimus or everolimus monotherapy to replace calcineurin inhibitors (CNI) in patients who underwent OLT for hepatocarcinoma or who developed *de novo* tumors have been recommended because of their antitumor properties, absence of nephrotoxicity, well tolerated adverse events, and potent immunosuppressive effect, which prevents rejection, especially in recipients with long-term follow-up who have developed some tolerance[123,131-134]. In our preliminary experience using sirolimus monotherapy in 16 patients who developed post-OLT malignancies we did not see any case of acute rejection during a mean follow-up of 15.7 months. The mean period elapsed from OLT to sirolimus monotherapy was 86 months, and the mean trough level of sirolimus was 8.9 ng/mL[131]. Recently, we published our experience of 57 patients (pts) using everolimus monotherapy (24 pts) or everolimus combined with low doses of CNI (33 pts) mainly in patients who underwent OLT for hepatocarcinoma (monotherapy, 9 pts; combined, 21 pts), or who developed *de novo* malignancies after OLT (monotherapy, 13 pts; combined, 6 pts); we observed only one case of acute rejection, improved renal function, and good tolerance of adverse effects [123]. In summary, independently of their antineoplastic efficacy, sirolimus and everolimus, in combination with low doses of CNI or as monotherapy at least one year after OLT, are safe and effective immunosuppresive drugs, which may be especially indicated in patients who underwent OLT for hepatocarcinoma or who are at high risk for development of *de novo* tumors (premalignant lesions, smokers or patients transplanted for AC).

**CONCLUSION**

Liver transplant recipients for AC are at higher risk than recipients with other etiologies for the development of post-OLT tumors, mainly due to frequent association of alcohol and tobacco consumption among these patients. *De novo* tumors related to AC patients are mainly located in the UAD tract, lung, skin and bladder-kidney. With the exception of skin tumors, these malignancies have very poor prognosis. Thus, strict surveillance (otolaryngeal exploration and yearly chest CT scan), and avoidance of alcohol and tobacco consumption should be advised to AC recipients in order to prevent the development of *de novo* malignancies or to obtain an early tumor diagnosis. Although the clinical antineoplastic efficacy of m-TORi is not yet unambiguously demonstrated, a decreased CNI dose or substitution with m-TORi after a minimun period of one year after OLT has been proposed in order to avoid hepatocarcinoma recurrence or the development of *de novo* tumors.

**REFERENCES**

1 **Jain AB**, Yee LD, Nalesnik MA, Youk A, Marsh G, Reyes J, Zak M, Rakela J, Irish W, Fung JJ. Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. *Transplantation* 1998; **66**: 1193-1200 [PMID: 9825817 DOI: 10.1097/00007890-199811150-00014]

2 **Sheiner PA**, Magliocca JF, Bodian CA, Kim-Schluger L, Altaca G, Guarrera JV, Emre S, Fishbein TM, Guy SR, Schwartz ME, Miller CM. Long-term medical complications in patients surviving & gt; or = 5 years after liver transplant. *Transplantation* 2000; **69**: 781-789 [PMID: 10755526 DOI: 10.1097/00007890-200003150-00018]

3 **Fung JJ**, Jain A, Kwak EJ, Kusne S, Dvorchik I, Eghtesad B. De novo malignancies after liver transplantation: a major cause of late death. *Liver Transpl* 2001; **7**: S109-S118 [PMID: 11689783 DOI: 10.1053/jlts.2001.28645]

4 **Penn I**. Cancers complicating organ transplantation. *N Engl J Med* 1990; **323**: 1767-1769 [PMID: 2247108 DOI: 10.1056/NEJM199012203232510]

5 **Haagsma EB**, Hagens VE, Schaapveld M, van den Berg AP, de Vries EG, Klompmaker IJ, Slooff MJ, Jansen PL. Increased cancer risk after liver transplantation: a population-based study. *J Hepatol* 2001; **34**: 84-91 [PMID: 11211912 DOI: 10.1016/S0168-8278(00)00077-5]

6 **Sanchez EQ**, Marubashi S, Jung G, Levy MF, Goldstein RM, Molmenti EP, Fasola CG, Gonwa TA, Jennings LW, Brooks BK, Klintmalm GB. De novo tumors after liver transplantation: a single-institution experience. *Liver Transpl* 2002; **8**: 285-291 [PMID: 11910575]

7 **Aberg F**, Pukkala E, Höckerstedt K, Sankila R, Isoniemi H. Risk of malignant neoplasms after liver transplantation: a population-based study. *Liver Transpl* 2008; **14**: 1428-1436 [PMID: 18825704 DOI: 10.1002/lt.21475]

8 **Peyrègne V**, Ducerf C, Adham M, de la Roche E, Berthoux N, Bancel B, Bizollon T, Baulieux J. De novo cancer after orthotopic liver transplantation. *Transplant Proc* 1998; **30**: 1484-1485 [PMID: 9636603 DOI: 10.1016/S0041-1345(98)00326-1]

9 **Duvoux C**, Delacroix I, Richardet JP, Roudot-Thoraval F, Métreau JM, Fagniez PL, Dhumeaux D, Cherqui D. Increased incidence of oropharyngeal squamous cell carcinomas after liver transplantation for alcoholic cirrhosis. *Transplantation* 1999; **67**: 418-421 [PMID: 10030289 DOI: 10.1097/00007890-199902150-00014]

10 **Jiménez C**, Marqués E, Loinaz C, Romano DR, Gómez R, Meneu JC, Hernández-Vallejo G, Alonso O, Abradelo M, Garcia I, Moreno E. Upper aerodigestive tract and lung tumors after liver transplantation. *Transplant Proc* 2003; **35**: 1900-1901 [PMID: 12962840 DOI: 10.1016/S0041-1345(03)00641-9]

11 **Benlloch S**, Berenguer M, Prieto M, Moreno R, San Juan F, Rayón M, Mir J, Segura A, Berenguer J. De novo internal neoplasms after liver transplantation: increased risk and aggressive behavior in recent years? *Am J Transplant* 2004; **4**: 596-604 [PMID: 15023152 DOI: 10.1111/j.1600-6143.2004.00380.x]

12 **Oo YH**, Gunson BK, Lancashire RJ, Cheng KK, Neuberger JM. Incidence of cancers following orthotopic liver transplantation in a single center: comparison with national cancer incidence rates for England and Wales. *Transplantation* 2005; **80**: 759-764 [PMID: 16210962 DOI: 10.1097/01.TP.0000173775.16579.18]

13 **Dumortier J**, Guillaud O, Adham M, Boucaud C, Delafosse B, Bouffard Y, Paliard P, Scoazec JY, Boillot O. Negative impact of de novo malignancies rather than alcohol relapse on survival after liver transplantation for alcoholic cirrhosis: a retrospective analysis of 305 patients in a single center. *Am J Gastroenterol* 2007; **102**: 1032-1041 [PMID: 17313502 DOI: 10.1111/j.1572-0241.2007.01079.x]

14 **Watt KD**, Pedersen RA, Kremers WK, Heimbach JK, Sanchez W, Gores GJ. Long-term probability of and mortality from de novo malignancy after liver transplantation. *Gastroenterology* 2009; **137**: 2010-2017 [PMID: 19766646 DOI: 10.1053/j.gastro.2009.08.070]

15 **Zanus G**, Carraro A, Vitale A, Gringeri E, D'Amico F, Valmasoni M, D'Amico FE, Brolese A, Boccagni P, Neri D, Srsen N, Burra P, Feltracco P, Bonsignore P, Scopelliti M, Cillo U. Alcohol abuse and de novo tumors in liver transplantation. *Transplant Proc* 2009; **41**: 1310-1312 [PMID: 19460548 DOI: 10.1016/j.transproceed.2009.03.055]

16 **Schrem H**, Kurok M, Kaltenborn A, Vogel A, Walter U, Zachau L, Manns MP, Klempnauer J, Kleine M. Incidence and long-term risk of de novo malignancies after liver transplantation with implications for prevention and detection. *Liver Transpl* 2013; **19**: 1252-1261 [PMID: 24106037 DOI: 10.1002/lt.23722]

17 **Jiang Y**, Villeneuve PJ, Fenton SS, Schaubel DE, Lilly L, Mao Y. Liver transplantation and subsequent risk of cancer: findings from a Canadian cohort study. *Liver Transpl* 2008; **14**: 1588-1597 [PMID: 18975293 DOI: 10.1002/lt.21554]

18 **Jonas S**, Rayes N, Neumann U, Neuhaus R, Bechstein WO, Guckelberger O, Tullius SG, Serke S, Neuhaus P. De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin. *Cancer* 1997; **80**: 1141-1150 [PMID: 9305716 DOI: 10.1002/(SICI)1097-0142(19970915)80: 6<1141: : AID-CNCR18>3.0.CO; 2-8]

19 **Fabia R**, Levy MF, Testa G, Obiekwe S, Goldstein RM, Husberg BS, Gonwa TA, Klintmalm GB. Colon carcinoma in patients undergoing liver transplantation. *Am J Surg* 1998; **176**: 265-269 [PMID: 9776156 DOI: 10.1016/S0002-9610(98)00141-X]

20 **Mithoefer AB**, Supran S, Freeman RB. Risk factors associated with the development of skin cancer after liver transplantation. *Liver Transpl* 2002; **8**: 939-944 [PMID: 12360438 DOI: 10.1053/jlts.2002.35551]

21 **Sanchez W**, Talwalkar JA, Gores GJ. "Will all liver transplantation patients eventually die from cancer?". *J Hepatol* 2006; **44**: 13-18 [PMID: 16297490 DOI: 10.1016/j.jhep.2005.10.007]

22 **Poynard T**, Barthelemy P, Fratte S, Boudjema K, Doffoel M, Vanlemmens C, Miguet JP, Mantion G, Messner M, Launois B. Evaluation of efficacy of liver transplantation in alcoholic cirrhosis by a case-control study and simulated controls. *Lancet* 1994; **344**: 502-507 [PMID: 7914613 DOI: 10.1016/S0140-6736(94)91897-X]

23 **Jain A**, DiMartini A, Kashyap R, Youk A, Rohal S, Fung J. Long-term follow-up after liver transplantation for alcoholic liver disease under tacrolimus. *Transplantation* 2000; **70**: 1335-1342 [PMID: 11087149 DOI: 10.1097/00007890-200011150-00012]

24 **Bellamy CO**, DiMartini AM, Ruppert K, Jain A, Dodson F, Torbenson M, Starzl TE, Fung JJ, Demetris AJ. Liver transplantation for alcoholic cirrhosis: long term follow-up and impact of disease recurrence. *Transplantation* 2001; **72**: 619-626 [PMID: 11544420 DOI: 10.1097/00007890-200108270-00010]

25 **Xiol X**, Guardiola J, Menendez S, Lama C, Figueras J, Marcoval J, Serrano T, Botargues JM, Mañer M, Rota R. Risk factors for development of de novo neoplasia after liver transplantation. *Liver Transpl* 2001; **7**: 971-975 [PMID: 11699033 DOI: 10/S1527646501059597]

26 **Saigal S**, Norris S, Muiesan P, Rela M, Heaton N, O'Grady J. Evidence of differential risk for posttransplantation malignancy based on pretransplantation cause in patients undergoing liver transplantation. *Liver Transpl* 2002; **8**: 482-487 [PMID: 12004349 DOI: 10/S152764650272162X]

27 **Jiménez-Romero C**, Manrique Municio A, Marqués Medina E, Colina F, Ortega Domene P, Gómez Sanz R, Meneu Diaz JC, Abradelo de Usera M, Moreno Elola A, Moreno Gonzalez E. Incidence of de novo nonmelanoma skin tumors after liver transplantation for alcoholic and nonalcoholic liver diseases. *Transplant Proc* 2006; **38**: 2505-2507 [PMID: 17097982 DOI: 10.1016/j.transproceed.2006.08.065]

28 **Jiménez C**, Manrique A, Marqués E, Ortega P, Loinaz C, Gómez R, Meneu JC, Abradelo M, Moreno A, López A, Moreno E. Incidence and risk factors for the development of lung tumors after liver transplantation. *Transpl Int* 2007; **20**: 57-63 [PMID: 17181654 DOI: 10.1111/j.1432-2277.2006.00397.x]

29 **Biselli M**, Gramenzi A, Del Gaudio M, Ravaioli M, Vitale G, Gitto S, Grazi GL, Pinna AD, Andreone P, Bernardi M. Long term follow-up and outcome of liver transplantation for alcoholic liver disease: a single center case-control study. *J Clin Gastroenterol* 2010; **44**: 52-57 [PMID: 19581813 DOI: 10.1097/MCG.0b013e3181a390a8.]

30 **Burra P**, Senzolo M, Adam R, Delvart V, Karam V, Germani G, Neuberger J. Liver transplantation for alcoholic liver disease in Europe: a study from the ELTR (European Liver Transplant Registry). *Am J Transplant* 2010; **10**: 138-148 [PMID: 19951276 DOI: 10.1111/j.1600-6143.2009.02869.x]

31 **Chak E**, Saab S. Risk factors and incidence of de novo malignancy in liver transplant recipients: a systematic review. *Liver Int* 2010; **30**: 1247-1258 [PMID: 20602682 DOI: 10.1111/j.1478-3231.2010.02303.x]

32 **Ettorre GM**, Piselli P, Galatioto L, Rendina M, Nudo F, Sforza D, Miglioresi L, Fantola G, Cimaglia C, Vennarecci G, Vizzini GB, Di Leo A, Rossi M, Tisone G, Zamboni F, Santoro R, Agresta A, Puro V, Serraino D. De novo malignancies following liver transplantation: results from a multicentric study in central and southern Italy, 1990-2008. *Transplant Proc* 2013; **45**: 2729-2732 [PMID: 24034034 DOI: 10.1016/j.transproceed.2013.07.050.]

33 **Kelly DM,** Emre S, Guy SR, Miller CM, Schwartz ME, Sheiner PA. Liver transplant recipients are not at increased risk for non-lymphoid solid organ tumors. *Cancer* 1998; **83**: 1237-1243 [PMID: 9740091]

34 **Galve ML**, Cuervas-Mons V, Figueras J, Herrero I, Mata M, Clemente G, Prieto M, Margarit C, Bernardos A, Casafont F. Incidence and outcome of de novo malignancies after liver transplantation. *Transplant Proc* 1999; **31**: 1275-1277 [PMID: 10083569 DOI: 10.1016/S0041-1345(98)01994-0]

35 **Jiménez C**, Rodríguez D, Marqués E, Loinaz C, Alonso O, Hernández-Vallejo G, Marín L, Rodríguez F, García I, Moreno E. De novo tumors after orthotopic liver transplantation. *Transplant Proc* 2002; **34**: 297-298 [PMID: 11959293 DOI: 10.1016/S0041-1345(01)02770-1]

36 **Herrero JI**, Lorenzo M, Quiroga J, Sangro B, Pardo F, Rotellar F, Alvarez-Cienfuegos J, Prieto J. De Novo neoplasia after liver transplantation: an analysis of risk factors and influence on survival. *Liver Transpl* 2005; **11**: 89-97 [PMID: 15690541 DOI: 10.1002/lt.20319]

37 **Baccarani U**, Piselli P, Serraino D, Adani GL, Lorenzin D, Gambato M, Buda A, Zanus G, Vitale A, De Paoli A, Cimaglia C, Bresadola V, Toniutto P, Risaliti A, Cillo U, Bresadola F, Burra P. Comparison of de novo tumours after liver transplantation with incidence rates from Italian cancer registries. *Dig Liver Dis* 2010; **42**: 55-60 [PMID: 19497797 DOI: 10.1016/j.dld.2009.04.017]

38 **Chatrath H**, Berman K, Vuppalanchi R, Slaven J, Kwo P, Tector AJ, Chalasani N, Ghabril M. De novo malignancy post-liver transplantation: a single center, population controlled study. *Clin Transplant* 2013; **27**: 582-590 [PMID: 23808800 DOI: 10.1111/ctr.12171]

39 **Collett D**, Mumford L, Banner NR, Neuberger J, Watson C. Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit. *Am J Transplant* 2010; **10**: 1889-1896 [PMID: 20659094 DOI: 10.1111/j.1600-6143.2010.03181.x.]

40 **Tjon AS**, Sint Nicolaas J, Kwekkeboom J, de Man RA, Kazemier G, Tilanus HW, Hansen BE, van der Laan LJ, Tha-In T, Metselaar HJ. Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C2 monitoring and recipient age. *Liver Transpl* 2010; **16**: 837-846 [PMID: 20583092 DOI: 10.1002/lt.22064]

41 **Engels EA**, Pfeiffer RM, Fraumeni JF, Kasiske BL, Israni AK, Snyder JJ, Wolfe RA, Goodrich NP, Bayakly AR, Clarke CA, Copeland G, Finch JL, Fleissner ML, Goodman MT, Kahn A, Koch L, Lynch CF, Madeleine MM, Pawlish K, Rao C, Williams MA, Castenson D, Curry M, Parsons R, Fant G, Lin M. Spectrum of cancer risk among US solid organ transplant recipients. *JAMA* 2011; **306**: 1891-1901 [PMID: 22045767 DOI: 10.1001/jama.2011.1592]

42 **Krynitz B**, Edgren G, Lindelöf B, Baecklund E, Brattström C, Wilczek H, Smedby KE. Risk of skin cancer and other malignancies in kidney, liver, heart and lung transplant recipients 1970 to 2008--a Swedish population-based study. *Int J Cancer* 2013; **132**: 1429-1438 [PMID: 22886725 DOI: 10.1002/ijc.27765]

43 **Sampaio MS**, Cho YW, Qazi Y, Bunnapradist S, Hutchinson IV, Shah T. Posttransplant malignancies in solid organ adult recipients: an analysis of the U.S. National Transplant Database. *Transplantation* 2012; **94**: 990-998 [PMID: 23085553 DOI: 10.1097/TP.0b013e318270bc7b]

44 **Wimmer CD**, Angele MK, Schwarz B, Pratschke S, Rentsch M, Khandoga A, Guba M, Jauch KW, Bruns C, Graeb C. Impact of cyclosporine versus tacrolimus on the incidence of de novo malignancy following liver transplantation: a single center experience with 609 patients. *Transpl Int* 2013; **26**: 999-1006 [PMID: 23952102 DOI: 10.1111/tri.12165]

45 **Marqués Medina E**, Jiménez Romero C, Gómez de la Cámara A, Rota Bernal A, Manrique Municio A, Moreno González E. Malignancy after liver transplantation: cumulative risk for development. *Transplant Proc* 2009; **41**: 2447-2449 [PMID: 19715947 DOI: 10.1016/j.transproceed.2009.06.153]

46 **Herrero JI**, Pardo F, D'Avola D, Alegre F, Rotellar F, Iñarrairaegui M, Martí P, Sangro B, Quiroga J. Risk factors of lung, head and neck, esophageal, and kidney and urinary tract carcinomas after liver transplantation: the effect of smoking withdrawal. *Liver Transpl* 2011; **17**: 402-408 [PMID: 21445923 DOI: 10.1002/lt.22247]

47 **DiMartini A**, Javed L, Russell S, Dew MA, Fitzgerald MG, Jain A, Fung J. Tobacco use following liver transplantation for alcoholic liver disease: an underestimated problem. *Liver Transpl* 2005; **11**: 679-683 [PMID: 15915490 DOI: 10.1002/lt.20385]

48 **Baris D**, Karagas MR, Verrill C, Johnson A, Andrew AS, Marsit CJ, Schwenn M, Colt JS, Cherala S, Samanic C, Waddell R, Cantor KP, Schned A, Rothman N, Lubin J, Fraumeni JF, Hoover RN, Kelsey KT, Silverman DT. A case-control study of smoking and bladder cancer risk: emergent patterns over time. *J Natl Cancer Inst* 2009; **101**: 1553-1561 [PMID: 19917915 DOI: 10.1093/jnci/djp361]

49 **Burling TA**, Ziff DC. Tobacco smoking: a comparison between alcohol and drug abuse inpatients. *Addict Behav* 1988; **13**: 185-190 [PMID: 3369328 DOI: 10.1016/0306-4603(88)90010-X]

50 **Batel P**, Pessione F, Maître C, Rueff B. Relationship between alcohol and tobacco dependencies among alcoholics who smoke. *Addiction* 1995; **90**: 977-980 [PMID: 7663320 DOI: 10.1046/j.1360-0443.1995.90797711.x]

51 **van der Heide F**, Dijkstra G, Porte RJ, Kleibeuker JH, Haagsma EB. Smoking behavior in liver transplant recipients. *Liver Transpl* 2009; **15**: 648-655 [PMID: 19479809 DOI: 10.1002/lt.21722]

52 **Fagerström K**. The epidemiology of smoking: health consequences and benefits of cessation. *Drugs* 2002; **62** Suppl 2: 1-9 [PMID: 12109931 DOI: 10.2165/00003495-200262002-00001]

53 **De Hertog SA CA**, Bastiaens MT, Kielich CJ, Berkhout MJ, Westendorp RG, Vermeer BJ, Bouwes Bavinck JN. Relation between smoking and skin cancer. *J Clin Oncol* 2001; **19**: 231-238 [PMID: 11134217]

54 **Leithead JA**, Ferguson JW, Hayes PC. Smoking-related morbidity and mortality following liver transplantation. *Liver Transpl* 2008; **14**: 1159-1164 [PMID: 18668649 DOI: 10.1002/lt.21471]

55 **Mashberg A**, Boffetta P, Winkelman R, Garfinkel L. Tobacco smoking, alcohol drinking, and cancer of the oral cavity and oropharynx among U.S. veterans. *Cancer* 1993; **72**: 1369-1375 [PMID: 8339227 DOI: 10.1002/1097-0142(19930815)72: 4<1369: : AID-CNCR2820720436>3.0.CO; 2-L]

56 **Kato I**, Nomura AM. Alcohol in the aetiology of upper aerodigestive tract cancer. *Eur J Cancer B Oral Oncol* 1994; **30B**: 75-81 [PMID: 8032304]

57 **Franceschi S**, Talamini R, Barra S, Barón AE, Negri E, Bidoli E, Serraino D, La Vecchia C. Smoking and drinking in relation to cancers of the oral cavity, pharynx, larynx, and esophagus in northern Italy. *Cancer Res* 1990; **50**: 6502-6507 [PMID: 2208109]

58 **Peto R**, Lopez AD, Boreham J, Thun M, Heath C. Mortality from tobacco in developed countries: indirect estimation from national vital statistics. *Lancet* 1992; **339**: 1268-1278 [PMID: 1349675 DOI: 10.1016/0140-6736(92)91600-D]

59 **Longnecker MP**. Alcohol consumption and risk of cancer in humans: an overview. *Alcohol* 1995; **12**: 87-96 [PMID: 7772271 DOI: 10.1016/0741-8329(94)00088-3]

60 **Castelli E**, Hrelia P, Maffei F, Fimognari C, Foschi FG, Caputo F, Cantelli-Forti G, Stefanini GF, Gasbarrini G. Indicators of genetic damage in alcoholics: reversibility after alcohol abstinence. *Hepatogastroenterology* 1999; **46**: 1664-1668 [PMID: 10430317]

61 **Boffetta P**, Hashibe M. Alcohol and cancer. *Lancet Oncol* 2006; **7**: 149-156 [PMID: 16455479 DOI: 10.1016/S1470-2045(06)70577-0]

62 **Thun MJ**, Peto R, Lopez AD, Monaco JH, Henley SJ, Heath CW, Doll R. Alcohol consumption and mortality among middle-aged and elderly U.S. adults. *N Engl J Med* 1997; **337**: 1705-1714 [PMID: 9392695 DOI: 10.1056/NEJM199712113372401]

63 **Wight AJ**, Ogden GR. Possible mechanisms by which alcohol may influence the development of oral cancer--a review. *Oral Oncol* 1998; **34**: 441-447 [PMID: 9930353 DOI: 10.1016/S1368-8375(98)00022-0]

64 **Voigt MD**. Alcohol in hepatocellular cancer. *Clin Liver Dis* 2005; **9**: 151-169 [PMID: 15763234 DOI: 10.1016/j.cld.2004.10.003]

65 **Singletary KW**, Gapstur SM. Alcohol and breast cancer: review of epidemiologic and experimental evidence and potential mechanisms. *JAMA* 2001; **286**: 2143-2151 [PMID: 11694156 DOI: 10.1001/jama.286.17.2143.]

66 **Molina PE**, Hoek JB, Nelson S, Guidot DM, Lang CH, Wands JR, Crawford JM. Mechanisms of alcohol-induced tissue injury. *Alcohol Clin Exp Res* 2003; **27**: 563-575 [PMID: 12658123 DOI: 10.1097/01.ALC.0000057946.57330.F7]

67 **Ehlers SL**, Rodrigue JR, Widows MR, Reed AI, Nelson DR. Tobacco use before and after liver transplantation: a single center survey and implications for clinical practice and research. *Liver Transpl* 2004; **10**: 412-417 [PMID: 15004770 DOI: 10.1002/lt.20087]

68 **Tollerud DJ**, Clark JW, Brown LM, Neuland CY, Mann DL, Pankiw-Trost LK, Blattner WA, Hoover RN. Association of cigarette smoking with decreased numbers of circulating natural killer cells. *Am Rev Respir Dis* 1989; **139**: 194-198 [PMID: 2912340 DOI: 10.1164/ajrccm/139.1.194]

69 **Goldstein DJ**, Austin JH, Zuech N, Williams DL, Stoopler MB, Michler RE, Schulman LL. Carcinoma of the lung after heart transplantation. *Transplantation* 1996; **62**: 772-775 [PMID: 8824476 DOI: 10.1097/00007890-199609270-00013]

70 **Romano DR**, Jiménez C, Rodríguez F, Loinaz C, Colina F, Ureña MA, García I, Moreno E. Orthotopic liver transplantation in alcoholic liver cirrhosis. *Transplant Proc* 1999; **31**: 2491-2493 [PMID: 10500685 DOI: 10.1016/S0041-1345(99)00432-7]

71 **Valero JM**, Rubio E, Moreno JM, Pons F, Sanchez-Turrion V, Cuervas-Mons V. De novo malignancies in liver transplantation. *Transplant Proc* 2003; **35**: 709-711 [PMID: 12644105 DOI: 10.1016/S0041-1345(03)00058-7]

72 **García-Sesma A**, Jiménez C, Loinaz C, Meneu JC, Colina F, Marqués E, Gómez R, Abradelo M, Garcia JI, Moreno González E. Kaposi's visceral sarcoma in liver transplant recipients. *Transplant Proc* 2003; **35**: 1898-1899 [PMID: 12962839 DOI: 10.1016/S0041-1345(03)00638-9]

73 **Veroux M**, Corona D, Scalia G, Garozzo V, Gagliano M, Giuffrida G, Costanzo CM, Giaquinta A, Palermo I, Zappalà D, Tallarita T, Zerbo D, Russo R, Cappellani A, Franchina C, Scriffignano V, Veroux P. Surveillance of human papilloma virus infection and cervical cancer in kidney transplant recipients: preliminary data. *Transplant Proc* 2009; **41**: 1191-1194 [PMID: 19460514 DOI: 10.1016/j.transproceed.2009.03.015]

74 **Kremers WK**, Devarbhavi HC, Wiesner RH, Krom RA, Macon WR, Habermann TM. Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival. *Am J Transplant* 2006; **6**: 1017-1024 [PMID: 16611339 DOI: 10.1111/j.1600-6143.2006.01294.x]

75 **Buell JF**, Brock GN. Risk of cancer in liver transplant recipients: a look into the mirror. *Liver Transpl* 2008; **14**: 1561-1563 [PMID: 18975288 DOI: 10.1002/lt.21634]

76 **Hojo M**, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, Shimbo T, Suthanthiran M. Cyclosporine induces cancer progression by a cell-autonomous mechanism. *Nature* 1999; **397**: 530-534 [PMID: 10028970 DOI: 10.1038/17401]

77 **André N**, Roquelaure B, Conrath J. Molecular effects of cyclosporine and oncogenesis: a new model. *Med Hypotheses* 2004; **63**: 647-652 [PMID: 15325009 DOI: 10.1016/j.mehy.2004.03.030]

78 **Buell JF**, Gross TG, Woodle ES. Malignancy after transplantation. *Transplantation* 2005; **80**: S254-S264 [PMID: 16251858 DOI: 10.1097/01.tp.0000186382.81130.ba]

79 **McAlister VC**, Haddad E, Renouf E, Malthaner RA, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. *Am J Transplant* 2006; **6**: 1578-1585 [PMID: 16827858 DOI: 10.1111/j.1600-6143.2006.01360.x]

80 **O'Donovan P**, Perrett CM, Zhang X, Montaner B, Xu YZ, Harwood CA, McGregor JM, Walker SL, Hanaoka F, Karran P. Azathioprine and UVA light generate mutagenic oxidative DNA damage. *Science* 2005; **309**: 1871-1874 [PMID: 16166520 DOI: 10.1126/science.1114233]

81 **Trotter JF**, Brazer SR. Rapid progression to high-grade dysplasia in Barrett's esophagus after liver transplantation. *Liver Transpl Surg* 1999; **5**: 332-333 [PMID: 10388506 DOI: 10.1002/lt.500050405]

82 **Ilan Y**, Shouval D, Galun E, Goldin E, Ligumsky M, Friedman G, Tur Kaspa R. Esophageal malignancy after liver transplantation in a patient with Barrett's esophagus. *Scand J Gastroenterol* 1996; **31**: 415-416 [PMID: 8726313 DOI: 10.3109/00365529609006420]

83 **Vera A**, Gunson BK, Ussatoff V, Nightingale P, Candinas D, Radley S, Mayer A, Buckels JA, McMaster P, Neuberger J, Mirza DF. Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. *Transplantation* 2003; **75**: 1983-1988 [PMID: 12829898 DOI: 10.1097/01.TP.0000058744.34965.38]

84 **Menachem Y**, Safadi R, Ashur Y, Ilan Y. Malignancy after liver transplantation in patients with premalignant conditions. *J Clin Gastroenterol* 2003; **36**: 436-439 [PMID: 12702989 DOI: 10.1097/00004836-200305000-00016]

85 **Williams RR**, Horm JW. Association of cancer sites with tobacco and alcohol consumption and socioeconomic status of patients: interview study from the Third National Cancer Survey. *J Natl Cancer Inst* 1977; **58**: 525-547 [PMID: 557114]

86 **Yu MC**, Garabrant DH, Peters JM, Mack TM. Tobacco, alcohol, diet, occupation, and carcinoma of the esophagus. *Cancer Res* 1988; **48**: 3843-3848 [PMID: 3378219]

87 **Terry P**, Lagergren J, Ye W, Nyrén O, Wolk A. Antioxidants and cancers of the esophagus and gastric cardia. *Int J Cancer* 2000; **87**: 750-754 [PMID: 10925371]

88 **Kenngott S**, Gerbes AL, Schauer R, Bilzer M. Rapid development of esophageal squamous cell carcinoma after liver transplantation for alcohol-induced cirrhosis. *Transpl Int* 2003; **16**: 639-641 [PMID: 12768231 DOI: 10.1111/j.1432-2277.2003.tb00363.x]

89 **Presser SJ**, Schumacher G, Neuhaus R, Thuss-Patience P, Stieler J, Neuhaus P. De novo esophageal neoplasia after liver transplantation. *Liver Transpl* 2007; **13**: 443-450 [PMID: 17318861 DOI: 10.1002/lt.21058]

90 **Meneu-Diaz JC**, Moreno-Gonzalez E, Garcia I, Moreno-Elola A, Jimenez C, Calvo Pulido J, Hidalgo Pascual M, Perez Saborido B, Jimenez Galanes S, Fundora Suarez Y, Marques E. Transhiatal esophagectomy for squamous cell carcinoma in liver transplant recipients. *Hepatogastroenterology* 2008; **55**: 1738-1741 [PMID: 19102381]

91 **Delcambre F**, Pruvot FR, Ramon P, Noël C, Pol A, Jaillard-Théry S, Dupont J, Declerck N, Gosselin B, Rémy-Jardin M, Wurtz A, Laffite JJ. Primary bronchogenic carcinoma in transplant recipients. *Transplant Proc* 1996; **28**: 2884-2885 [PMID: 8908109]

92 **Frezza EE**, Fung JJ, van Thiel DH. Non-lymphoid cancer after liver transplantation. *Hepatogastroenterology* ; **44**: 1172-1181 [PMID: 9261620]

93 **de Perrot M**, Wigle DA, Pierre AF, Tsao MS, Waddell TK, Todd TR, Keshavjee SH. Bronchogenic carcinoma after solid organ transplantation. *Ann Thorac Surg* 2003; **75**: 367-371 [PMID: 12607641 DOI: 10.1016/S0003-4975(02)04379-5]

94 **Grupo de estudio de carcinoma broncogénico de SOCALPAR.** Incidencia del carcinoma broncogénico en Castilla y León durante el año 1997. Estudio multicéntrico de la Sociedad Castellano Leonesa de Patología Respiratoria (SOCALPAR). *Arch Bronconeumol* 2000; **36**: 313-318

95 **Génébès C**, Brouchet L, Kamar N, Lepage B, Prévot G, Rostaing L, Didier A, Mazières J. Characteristics of thoracic malignancies that occur after solid-organ transplantation. *J Thorac Oncol* 2010; **5**: 1789-1795 [PMID: 20975378 DOI: 10.1097/JTO.0b013e3181f19226]

96 **Arcasoy SM**, Hersh C, Christie JD, Zisman D, Pochettino A, Rosengard BR, Blumenthal NP, Palevsky HI, Bavaria JE, Kotloff RM. Bronchogenic carcinoma complicating lung transplantation. *J Heart Lung Transplant* 2001; **20**: 1044-1053 [PMID: 11595559 DOI: 10.1016/S1053-2498(01)00301-1]

97 **Rosenbaum DH**, Bhojani RA, Dikmen E, Kaiser PA, Paul MC, Wait MA, Meyer DM, Jessen ME, Yancy CW, Rosenblatt RL, Torres F, Perkins S, Ring WS, DiMaio JM. Routine computed tomography screening of the chest in high-risk cardiac transplant recipients may improve survival. *J Heart Lung Transplant* 2005; **24**: 2043-2047 [PMID: 16364847 DOI: 10.1016/j.healun.2005.06.020]

98 **Finkenstedt A**, Graziadei IW, Oberaigner W, Hilbe W, Nachbaur K, Mark W, Margreiter R, Vogel W. Extensive surveillance promotes early diagnosis and improved survival of de novo malignancies in liver transplant recipients. *Am J Transplant* 2009; **9**: 2355-2361 [PMID: 19663894 DOI: 10.1111/j.1600-6143.2009.02766.x]

99 **Euvrard S**, Kanitakis J, Claudy A. Skin cancers after organ transplantation. *N Engl J Med* 2003; **348**: 1681-1691 [PMID: 12711744 DOI: 10.1056/NEJMra022137]

100 **Vallejo GH**, Romero CJ, de Vicente JC. Incidence and risk factors for cancer after liver transplantation. *Crit Rev Oncol Hematol* 2005; **56**: 87-99 [PMID: 15979889 DOI: 10.1016/j.critrevonc.2004.12.011]

101 **Jain A**, Patil VP, Fung J. Incidence of de novo cancer and lymphoproliferative disorders after liver transplantation in relation to age and duration of follow-up. *Liver Transpl* 2008; **14**: 1406-1411 [PMID: 18825680 DOI: 10.1002/lt.21609]

102 **Tessari G**, Naldi L, Boschiero L, Nacchia F, Fior F, Forni A, Rugiu C, Faggian G, Sassi F, Gotti E, Fiocchi R, Talamini G, Girolomoni G. Incidence and clinical predictors of a subsequent nonmelanoma skin cancer in solid organ transplant recipients with a first nonmelanoma skin cancer: a multicenter cohort study. *Arch Dermatol* 2010; **146**: 294-299 [PMID: 20231501 DOI: 10.1001/archdermatol.2009.377]

103 **Levy M**, Backman L, Husberg B, Goldstein R, McMillan R, Gibbs J, Gonwa TA, Holman M, Klintmalm G. De novo malignancy following liver transplantation: a single-center study. *Transplant Proc* 1993; **25**: 1397-1399 [PMID: 8442153]

104 **Jacobson LP**, Armenian HK. An integrated approach to the epidemiology of Kaposi's sarcoma. *Curr Opin Oncol* 1995; **7**: 450-455 [PMID: 8541391 DOI: 10.1097/00001622-199509000-00011]

105 **Aseni P**, Vertemati M, Minola E, Arcieri K, Bonacina E, Camozzi M, Osio C, Forti D. Kaposi's sarcoma in liver transplant recipients: morphological and clinical description. *Liver Transpl* 2001; **7**: 816-823 [PMID: 11552218 DOI: 10/S1527646501014605]

106 **Euvrard S**, Kanitakis J, Bosshard S, Lebbé C, Garnier JL, Touraine JL, Claudy A. No recurrence of posttransplantation Kaposi's sarcoma three years after renal retransplantation. *Transplantation* 2002; **73**: 297-299 [PMID: 11821747 DOI: 10.1097/00007890-200201270-00025]

107 **Otley CC**, Pittelkow MR. Skin cancer in liver transplant recipients. *Liver Transpl* 2000; **6**: 253-262 [PMID: 10827224 DOI: 10/S1527646500870082]

108 **Zeegers MP**, Kellen E, Buntinx F, van den Brandt PA. The association between smoking, beverage consumption, diet and bladder cancer: a systematic literature review. *World J Urol* 2004; **21**: 392-401 [PMID: 14685762 DOI: 10.1007/s00345-003-0382-8]

109 **Samanic C**, Kogevinas M, Dosemeci M, Malats N, Real FX, Garcia-Closas M, Serra C, Carrato A, García-Closas R, Sala M, Lloreta J, Tardón A, Rothman N, Silverman DT. Smoking and bladder cancer in Spain: effects of tobacco type, timing, environmental tobacco smoke, and gender. *Cancer Epidemiol Biomarkers Prev* 2006; **15**: 1348-1354 [PMID: 16835335 DOI: 10.1158/1055-9965.EPI-06-0021]

110 **Yao FY**, Gautam M, Palese C, Rebres R, Terrault N, Roberts JP, Peters MG. De novo malignancies following liver transplantation: a case-control study with long-term follow-up. *Clin Transplant* 2006; **20**: 617-623 [PMID: 16968488 DOI: 10.1111/j.1399-0012.2006.00527.x]

111 **Zaman A**, Hapke R, Flora K, Rosen H, Benner K. Prevalence of upper and lower gastrointestinal tract findings in liver transplant candidates undergoing screening endoscopic evaluation. *Am J Gastroenterol* 1999; **94**: 895-899 [PMID: 10201453 DOI: 10.1111/j.1572-0241.1999.984\_g.x]

112 **Ulrich C**, Jürgensen JS, Degen A, Hackethal M, Ulrich M, Patel MJ, Eberle J, Terhorst D, Sterry W, Stockfleth E. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. *Br J Dermatol* 2009; **161** Suppl 3: 78-84 [PMID: 19775361 DOI: 10.1111/j.1365-2133.2009.09453.x]

113 **Chandok N**, Watt KD. Burden of de novo malignancy in the liver transplant recipient. *Liver Transpl* 2012; **18**: 1277-1289 [PMID: 22887956 DOI: 10.1002/lt.23531]

114 **Herrero JI**, Alegre F, Quiroga J, Pardo F, Iñarrairaegui M, Sangro B, Rotellar F, Montiel C, Prieto J. Usefulness of a program of neoplasia surveillance in liver transplantation. A preliminary report. *Clin Transplant* 2009; **23**: 532-536 [PMID: 19681977 DOI: 10.1111/j.1399-0012.2008.00927.x]

115 **Ojo AO**, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, Arndorfer J, Christensen L, Merion RM. Chronic renal failure after transplantation of a nonrenal organ. *N Engl J Med* 2003; **349**: 931-940 [PMID: 12954741 DOI: 10.1056/NEJMoa021744]

116 **Guba M**, Graeb C, Jauch KW, Geissler EK. Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. *Transplantation* 2004; **77**: 1777-1782 [PMID: 15223891 DOI: 10.1097/01.TP.0000120181.89206.54]

117 **Gaumann A**, Schlitt HJ, Geissler EK. Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin. *Transpl Int* 2008; **21**: 207-217 [PMID: 18069922 DOI: 10.1111/j.1432-2277.2007.00610.x]

118 **Dantal J**, Hourmant M, Cantarovich D, Giral M, Blancho G, Dreno B, Soulillou JP. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. *Lancet* 1998; **351**: 623-628 [PMID: 9500317 DOI: 10.1016/S0140-6736(97)08496-1]

119 **Carter SB**, Franklin TJ, Jones DF, Leonard BJ, Mills SD, Turner RW, Turner WB. Mycophenolic acid: an anti-cancer compound with unusual properties. *Nature* 1969; **223**: 848-850 [PMID: 5799033 DOI: 10.1038/223848a0]

120 **Engl T**, Makarević J, Relja B, Natsheh I, Müller I, Beecken WD, Jonas D, Blaheta RA. Mycophenolate mofetil modulates adhesion receptors of the beta1 integrin family on tumor cells: impact on tumor recurrence and malignancy. *BMC Cancer* 2005; **5**: 4 [PMID: 15644133 DOI: 10.1186/1471-2407-5-4]

121 **Guba M**, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. *Nat Med* 2002; **8**: 128-135 [PMID: 11821896 DOI: 10.1038/nm0202-128]

122 **Koehl GE**, Andrassy J, Guba M, Richter S, Kroemer A, Scherer MN, Steinbauer M, Graeb C, Schlitt HJ, Jauch KW, Geissler EK. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. *Transplantation* 2004; **77**: 1319-1326 [PMID: 15167584 DOI: 10.1097/00007890-200405150-00002]

123 **Alegre C**, Jiménez C, Manrique A, Abradelo M, Calvo J, Loinaz C, García-Sesma A, Cambra F, Alvaro E, García M, Sanabria R, Justo I, Caso O, Moreno E. Everolimus monotherapy or combined therapy in liver transplantation: indications and results. *Transplant Proc* 2013; **45**: 1971-1974 [PMID: 23769086 DOI: 10.1016/j.transproceed.2013.01.075]

124 **Rodríguez-Perálvarez M**, De la Mata M, Burroughs AK. Liver transplantation: immunosuppression and oncology. *Curr Opin Organ Transplant* 2014; **19**: 253-260 [PMID: 24685671 DOI: 10.1097/MOT.0000000000000069]

125 **Kauffman HM**, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. *Transplantation* 2005; **80**: 883-889 [PMID: 16249734 DOI: 10.1097/01.TP.0000184006.43152.8D]

126 **Campistol JM**, Eris J, Oberbauer R, Friend P, Hutchison B, Morales JM, Claesson K, Stallone G, Russ G, Rostaing L, Kreis H, Burke JT, Brault Y, Scarola JA, Neylan JF. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. *J Am Soc Nephrol* 2006; **17**: 581-589 [PMID: 16434506]

127 **Campistol JM**, Gutierrez-Dalmau A, Torregrosa JV. Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma. *Transplantation* 2004; **77**: 760-762 [PMID: 15021843 DOI: 10.1097/01.TP.0000115344.18025.0B]

128 **Sierka D,** Kumar MSA, Heifets M, Parikh M, Moritz MJ, Kumar A. Successful minimization of immunosuppression and conversion to sirolimus in kidney transplant recipients with post transplant lymphoproliferative disease and de novo non-skin malignancies. *Am J Transplant* 2004; **4** Suppl 8: 523

129 **Schnitzbauer AA**, Zuelke C, Graeb C, Rochon J, Bilbao I, Burra P, de Jong KP, Duvoux C, Kneteman NM, Adam R, Bechstein WO, Becker T, Beckebaum S, Chazouillères O, Cillo U, Colledan M, Fändrich F, Gugenheim J, Hauss JP, Heise M, Hidalgo E, Jamieson N, Königsrainer A, Lamby PE, Lerut JP, Mäkisalo H, Margreiter R, Mazzaferro V, Mutzbauer I, Otto G, Pageaux GP, Pinna AD, Pirenne J, Rizell M, Rossi G, Rostaing L, Roy A, Turrion VS, Schmidt J, Troisi RI, van Hoek B, Valente U, Wolf P, Wolters H, Mirza DF, Scholz T, Steininger R, Soderdahl G, Strasser SI, Jauch KW, Neuhaus P, Schlitt HJ, Geissler EK. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. *BMC Cancer* 2010; **10**: 190 [PMID: 20459775 DOI: 10.1186/1471-2407-10-190]

130 **Monaco AP**. The role of mTOR inhibitors in the management of posttransplant malignancy. *Transplantation* 2009; **87**: 157-163 [PMID: 19155967 DOI: 10.1097/TP.0b013e318193886e]

131 **Jiménez-Romero C**, Manrique A, Marqués E, Calvo J, Sesma AG, Cambra F, Abradelo M, Sterup RM, Olivares S, Justo I, Colina F, Moreno E. Switching to sirolimus monotherapy for de novo tumors after liver transplantation. A preliminary experience. *Hepatogastroenterology* 2011; **58**: 115-121 [PMID: 21510297]

132 **Sánchez G,** García F, Lorenzo S, Herranz MT, Almohalla C, Velicia R, Caro A. Indications and effectiveness of the mammalian target of rapamycin in liver transplantation. *Transplant Proc* 2011; **43**: 714-717 [PMID: 21486581 DOI: 10.1016/j.transproceed.2011.01.105]

133 **Alamo JM**, Bernal C, Marín LM, Suárez G, Serrano J, Barrera L, Sousa JM, Padillo FJ, Gómez-Bravo MA. Antitumor efficacy of mammalian target of rapamycin inhibitor therapy in liver transplant recipients with oncological disease: a case-control study. *Transplant Proc* 2012; **44**: 2089-2092 [PMID: 22974919 DOI: 10.1016/j.transproceed.2012.07.079]

134 **Liang W**, Wang D, Ling X, Kao AA, Kong Y, Shang Y, Guo Z, He X. Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis. *Liver Transpl* 2012; **18**: 62-69 [PMID: 21964956 DOI: 10.1002/lt.22441]

**P-Reviewer:** Grassi A, Marino IR, Rodriguez-Peralvarez M

**S-Editor:** Tian YL **L-Editor: E-Editor:**

**Table 1 Overall incidence of *de novo* tumors after liver transplantation**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **No. OLT** | **Follow-up period** | **Time from OLT-DNT** | **Pts with DNT** | **DNT incidence *n* (%)** | **Overall SIR** |
| Jonas *et al*[18] | 458 | 50/22 mo | 43 mo | 33 | 34 (7.2) | - |
| Jain *et al*[1] | 1000 | 78 mo | 36 mo | 57 | 58 (5.7) | 7.6 (UAD) |
| Kelly *et al*[33] | 888 | 29.3 ± 25.2 mo | 24 ± 16.8 mo | 39 | 43 (4.8) | - |
| Peyregne *et al*[8] | 251 | 50.5 mo | 24.3 mo | 11 | 12 (4.8) | - |
| Galve *et al*[34] | 1827 | 20 ± 18 mo | 30.7 ± 22 mo | 70 | 70 (3.8) | - |
| Sheiner *et al*[2] | 121 | 499 persons/yr | 19.2 mo | 18 | 19 (15.7) | 3.9 |
| Haagsma *et al*[5] | 174 | 61 mo | - | 21 | 23 (13.2) | - |
| Xiol *et al*[25] | 137 | 69 mo | 12-104 mo | 22 | 30 (21.9) | - |
| Jiménez *et al* [35] | 505 | 8-168 mo | 47.8 mo | 57 | 62 (12.2) | - |
| Saigal *et al*[26] | 1140 | 69 mo | 45 mo | 30 | 30 (2.6) | - |
| Sánchez *et al*[6] | 1421 | 67 mo | - | 125 | 125 (8.8) | - |
| Benlloch *et al*[11] | 772 | 51 mo | 40 mo | 41 | 41 (5.3) | - |
| Herrero *et al*[36] | 187 | 65 mo | 49.5 mo | 49 | 63 (33.6) | - |
| Oo *et al*[12] | 1778 | - | 57 mo | 141 | 141 (7.9) | 2.07 |
| Aberg *et al*[7] | 540 | 3222 persons/yr | 61 mo | 47 | 50 (9.2) | 2.59 |
| Jiang *et al*[17] | 2034 | - | 42.2 ± 33.8 mo | 113 | 113 (5.5) | 2.5 |
| Baccarini *et al*[37] | 417 | 81.6 mo | 51 mo | 43 | 43 (10.3) | 2.7 |
| Chatrath *et al*[38] | 534 | 68 ± 38.4 mo | 48 ± 26.4 mo | 73 | 80 (14.9) | 3.1 |
| Collet *et al*[39] | 6846 | - | - | - | - | 2.2 |
| Tjon *et al*[40] | 385 | > 4 mo | - | 50 | 66 (17.1) | 2.2 |
| Engels *et al*[41] | 6291 | - | - | - | - | 2.2 |
| Krinitz *et al* [42] | 1221 | 61.2 mo | - | 150 | 150 (12.3) | 3.4 |
| Sampaio *et al*[43] | 43216 | - | 31.2 mo | 1923 | 1923 (4.4) | - |
| Ettore *et al*[32] | 1675 | 62.4 mo | 38.4 mo | 98 | 100 (5.9) | 1.4 |
| Schrem *et al*[16] | 2000 | - | 82.7 mo | 115 | 120 (6) | 1.94 |
| Wimmer *et al*[44] | 609 | 57.3 mo | 68.4 ± 44.4 mo | 71 | 87 (14.3) | - |

OLT: Orthotopic liver transplantation; DNT: *De novo* tumors; UAD: Upper aerodigestive tumor.

**Table 2 Comparative studies between alcoholic cirrhotic and non-alcoholic cirrhotic patients who underwent orthotopic liver transplantation, incidence of** ***de novo* tumors *n* (%)**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **No. OLT** | **Follow-up period** | **DNT overall incidence**  | **DNT-AC** | **DNT-non-AC** | **P-value** | **DNT excluded** |
| Duvoux *et a* [9] | 90 | 45.2 ± 21.2 mo | 11 (12.2) | 8 (26.7) | 3 (5) | 0.01 | - |
| Jain *et al*[23] | 834 | 9 4 ±11 mo | 81 (9.7) | 36 (19.4) | 45 (6.9) | < 0.05 (UAD) | - |
| Bellamy *et al*[24] | 513 | 81.7 mo | 57 (11.3) | 33 (26) | 24 (6.1) | 0.0001 | PTLD |
| Saigal *et al*[26] | 1140 | 69 mo | 30 (2.6) | 10 (7.5) | 20 (1) | 0.001 | - |
| Benlloch *et al*[11] | 772 | 40 mo | 41 (5.3) | 18 (9.4) | 23 (3.9) | 0.01 | Skin DNT |
| Oo *et al*[12] | 1778 | - | 141 (7.9) | 15 (8.8) | 126 (7.8) | 0.001 | - |
| Dumortier *et al*[13]  | 594 | - | 42 (7) | 37 (12.1) | 5 (1.7) | 0.05 | - |
| Jiménez *et al*[28] | 701 | 9-206 mo | 109 (15.5) | 69 (25) | 40 (9.4) | 0.001 | - |
| Biselli *et al*[29] | 147 | - | 11 (7.5) | 7 (14.3) | 4 (4) | 0.042 | - |
| Zanus *et al*[15] | 638 | 48 mo | 43 (6.3) | 16 (11) | 27 (5) | 0.02 | - |

AC: Alcoholic cirrhosis; OLT: Orthotopic liver transplantation; PTLD: Post-transplant lymphoproliferative disease; DNT: *De novo* tumors; UAD: Upper aerodigestive tumor.

**Table 3 Location and risk factors for the most frequent *de novo* tumors in patients who underwent orthotopic liver transplantation for alcoholic cirrhosis**

|  |  |
| --- | --- |
| **Tumor location** | **Risk factors** |
| **UAD** | Alcoholic cirrhosis[9-11,13-15,23,24,30] |
| Tobacco consumption[9,14,38,46] |
| Barrett´s esophagus[82] |
| **Lung** | Alcoholic cirrhosis[14,28]Tobacco consumption[1,28,38,46] |
| **Skin** | Alcoholic cirrhosis[24,26,27] |
| Tobacco consumption[20,27,51] |
| Age > 40 yr[20] or Age > 51 yr[25] |
| Male, red hair, brown eyes[20] |
| Sun exposure[20,36] |
| Sclerosing cholangitis[20] |
| CyA immunosuppression[20] |
| **Kidney and****genitourinary tract** | Tobacco consumption[46] |

CyA: Cycosporine A; UAD: Upper aerodigestive tumor.